Life Sciences
Top stories summarized by our editors
7/19/2019

Microfocused ultrasound with visualization safely improved the symptoms of erythematotelangiectatic rosacea in a study published in the Journal of Drugs in Dermatology. "A single, high-density [microfocused ultrasound with visualization] treatment may be the most efficacious for treating erythematotelangiectatic rosacea," the researchers said.

Full Story:
Dermatology Advisor
7/19/2019

SeaSpine has expanded its OsteoStrand portfolio, which includes OsteoStrand and OsteoStrand Plus Demineralized Bone Fibers, adding an integrated hydration syringe system.

Full Story:
Becker's Spine Review
More Summaries:
SeaSpine
7/19/2019

Becton Dickinson is recalling some Alaris Pump Model 1800 infusion sets because of the potential for unintended delivery of drugs or faster-than-expected delivery of drugs. The problem is thought to be related to non-uniform thickness of the silicon segment.

Full Story:
Seeking Alpha
More Summaries:
Becton Dickinson
7/19/2019

Alphatec has launched its anterior lumbar interbody fusion device called IdentiTi Large Window Porous Titanium Interbody implant system. The device has pore structure to generate surface roughness, which promotes surface adhesion and improves implant stability.

Full Story:
Becker's Spine Review
More Summaries:
Alphatec
7/19/2019

Havas Health & You has launched a new division dedicated to cannabinoids, with a focus on education as opposed to science-based programs. The firm, called Havas ECS, will operate out of Havas' New York and New Jersey offices and will hold a conference this fall.

Full Story:
MM&M
More Summaries:
Havas
7/19/2019

Capricor Therapeutics reported promising mid-stage results from an ongoing clinical trial of a cell-based therapy that strengthens skeletal muscles and pulmonary and cardiac function in people with Duchenne muscular dystrophy. Cofounder and CEO Linda Marban says Capricor executives will meet with FDA officials soon to discuss a Phase III trial and said the company is considering options for bolstering its financial position and may seek equity financing, a private placement or NIH grants.

7/19/2019

GlaxoSmithKline CEO Emma Walmsley is taking a different path than executives at some rival drug firms, divesting experimental drugs, replacing most of her top managers, cutting some 3,800 employees, and entering a joint venture with Pfizer for consumer products. Walmsley is boosting GSK's oncology pipeline and carefully selecting potentially lucrative opportunities rather than large takeovers as she works to achieve a culture shift.

7/19/2019

Respira Labs founder Maria Artunduaga is among the 40 Silicon Valley entrepreneurs younger than 40 gaining recognition for career growth and community contributions. Artunduaga is a longtime advocate for inclusivity in STEM, participates in Association for Women in Science mentorship programs and has been lobbying for a ministry of science and technology in her native Colombia.

7/19/2019

European Commission President Ursula von der Leyen, the first woman to lead the EU's executive branch, says climate change is at the top of her agenda and will announce a so-called Green Deal for Europe that includes a biodiversity strategy, an extended emissions-trading system and a carbon leakage tax. Von der Leyen will need to gain the support of EU member states to implement her climate agenda.

Full Story:
Nature (free content)
7/19/2019

Science is uncertain and its pursuit is prone to failure, but scientists shouldn't take failure personally, says neuroscientist Miriam Goodman, deputy director of the Stanford Neuroscience Institute. Goodman as well as two postdoctoral fellows and two graduate students in her lab discuss their work and what paths they might take.

Full Story:
Stanford University